US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

Stockholm, Sweden, March 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805. ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The antibody is being evaluated as a disease modifying treatment for Parkinson’s disease. ABBV-0805 is a result

BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805

· ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805. This is a requirement to start clinical trials in the U.S. ABBV-0805, previously named BAN0805, is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The

BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance

Stockholm, Sweden, December 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic’s alpha-synuclein antibody portfolio for Parkinson’s disease and other potential indications to AbbVie. On November 2, 2018, BioArctic announced that the company had received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie and BioArctic. The exercise of the option was

BioArctic is awarded grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s

Stockholm, Sweden, November 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been awarded a grant from EU’s research and innovation program Horizon 2020. The grant (Grant Agreement No. 813528) has been obtained for the company’s participation in a European consortium working for collaboration between the pharma industry and European universities. It is also the task of the consortium to educate the next generation of researchers and to encourage entrepreneurship in the area of diagnostics of neurodegenerative diseases such as Parkinson’s disease. The educational part falls

BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease

Stockholm, Sweden, November 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie (NYSE: ABBV) and BioArctic. The option is subject to filing and clearance under the US Antitrust legislation. BioArctic and AbbVie, a global biopharmaceutical company, in 2016 entered into a strategically important collaboration to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein

BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease

Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant the company’s patent application in Europe, EP09738534.8, for its Parkinson’s disease concept patent. The decision states that the European patent, EP 2 282 758 B1, will enter into force on November 21, 2018. The granted concept patent in Europe protects the company’s innovative treatment strategy for Parkinson’s disease. Corresponding patents have previously been granted in the US and Japan. BioArctic’s patent

BioArctic receives this year’s SwedenBIO Award

Stockholm, Sweden, May 16, 2018 – BioArctic AB today received the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by contributing to societal benefit emphasizing the importance of a successful life science industry in Sweden. SwedenBIO rewards BioArctic for the company’s strong collaborations with academia as well as global pharma companies, and a high scientific ambition, which has given BioArctic a portfolio of innovative projects for the treatment of diseases of the central nervous system, an area with growing medical and societal needs. SwedenBIO

BioArctic presents Nomination Committee and publishes financial calendar 2018

Stockholm, Sweden, November 9, 2017 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 31, 2017 the members of the Nomination Committee for the 2018 Annual General Meeting shall be appointed through a procedure where the three largest shareholders in terms of voting power according to Euroclear’s transcription of the share register as of September 30, 2017 are contacted by the Chairman of the Board and asked to appoint one representative each to the Nomination Committee. If any of the three largest shareholders does not wish to appoint a member of the

Invitation to presentation of BioArctic’s Interim Report January – September 2017 on November 8

Stockholm, Sweden, November 3, 2017 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publishes the company’s Interim Report for the period January – September 2017 on November 8, 2017 at 08:00 a.m. CET.BioArctic invites you to an audiocast with teleconference (in English) for investors, analysts and media on November 8, at 09:30 – 10:30 a.m. CET. Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Interim Report for the period January – September 2017 followed by a Q&A-session. To attend, see below: Please dial-in at one of the numbers below, from:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media